Overview

Study Evaluating Isovorin in Colon Cancer

Status:
Completed

Trial end date:
2006-02-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to verify superiority of 1-LV/5FU therapy to UFT Therapy of relapse-free survival time in patients with Dukes C and Cure A colon cancer. Secondary endpoints include disease-free survival time, survival time, and safety.

Phase:

Phase 3

Details

Lead Sponsor:

Wyeth is now a wholly owned subsidiary of Pfizer

Treatments:

Leucovorin
Levoleucovorin